Mycosis Fungoides Treatments

Find Mycosis Fungoides Treatments

Brand Name

Poteligeo

Generic Name

Mogamulizumab-Kpkc

View Brand Information

FDA approval date: August 08, 2018

Classification: Chemokine Receptor Type 4 Interaction

Form: Injection

What is Poteligeo (Mogamulizumab-Kpkc)?

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 -directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy .

Approved To Treat

Top Global Experts

Farah Abdulla

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

Who is this study for: Patients with Lymphoma

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Other, Drug, Biological

Study Drugs: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy

Study Phase: Phase 1

Summary: This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body'...

A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

Who is this study for: Patients with erythrodermic cutaneous T cell lymphoma

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Other, Procedure, Biological

Study Drug: Mogamulizumab

Study Phase: Phase 2

Summary: This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with ...

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Enrollment Status: Recruiting

Publish Date: September 22, 2025

Intervention Type: Drug

Summary: The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.

View All Clinical Trials

Related Latest Advances

The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.

Journal: Journal of investigative medicine high impact case reports

Published: August 19, 2023

Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous T-cell lymphoma on quality of life.

Journal: Skin health and disease

Published: June 10, 2023

Strategies for Glycoengineering Therapeutic Proteins.

Journal: Frontiers in chemistry

Published: January 26, 2022

View All Latest Advances